On Thursday, Truist Securities adjusted its stock price target for Eli Lilly (NYSE:LLY) shares, bringing it down slightly to $1,029 from the previous $1,033 while still maintaining a Buy rating on the stock. The adjustment follows the company's recent performance and market dynamics.
The firm's analyst pointed to the sustained demand for treatments for type 2 diabetes (T2D) and obesity as a key driver for Eli Lilly's growth. The analyst believes that the current market weakness presents an opportunity for investors to buy into the stock. This optimism is based on positive quarter-over-quarter prescription growth and management's confidence that this trend could continue into the fourth quarter.
Eli Lilly is also expected to benefit from international launches slated for the fourth quarter, which are anticipated to bolster sales outside the United States. Moreover, there are plans to increase direct-to-consumer (DTC) marketing efforts to reach more patients.
The analyst highlighted the fact that the obesity market penetration is still at a low single-digit level, approximately 4-5%, and with Eli Lilly's treatment TZP projected to reach sales of around $12 to $13 billion in the fiscal year 2024, there remains a significant market opportunity. The total addressable market for these treatments is estimated to be well over $100 billion, which also bodes well for related products in the pharmaceutical sector.
In summary, Truist Securities reaffirms its Buy rating for Eli Lilly with a revised price target of $1,029, down from $1,033, citing the company's potential for substantial growth in the T2D and obesity markets.
In other recent news, Eli Lilly has reported significant growth in its third-quarter earnings, with a notable 42% increase in revenue. This growth was largely driven by sales of its diabetes and cancer drugs, Mounjaro and Zepbound, which surpassed $3 billion. The company's earnings per share also increased to $1.18 from $0.10 in the same quarter the previous year.
Eli Lilly has raised its revenue guidance for 2024 to between $45.4 billion and $46 billion, expecting a 50% growth in the fourth quarter. Its strategic investments, including $2 billion in Ireland and $4.5 billion for the Lilly Medicine Foundry in Indiana, have been instrumental in its continued expansion.
Key pipeline achievements included new U.S. approvals for Ebglyss and Kisunla and positive study data for tirzepatide and donanemab. Despite facing some physical and financial constraints affecting customer service levels, Eli Lilly remains confident in its growth trajectory and robust pipeline progress. These recent developments indicate a strong performance and strategic positioning for future growth.
InvestingPro Insights
Eli Lilly's strong market position and growth potential, as highlighted in the article, are further supported by recent InvestingPro data.
The company's revenue growth of 31.87% over the last twelve months and an impressive 35.98% growth in the most recent quarter underscore its robust performance in the pharmaceutical sector. This aligns with the analyst's positive outlook on Eli Lilly's growth prospects, particularly in the diabetes and obesity treatment markets.
InvestingPro Tips reveal that Eli Lilly has raised its dividend for 10 consecutive years and has maintained dividend payments for 54 consecutive years, demonstrating a commitment to shareholder returns. This consistency in dividend growth could be particularly attractive to investors looking for stable income alongside potential capital appreciation.
The company's high return over the last year and decade, as noted in the InvestingPro Tips, further supports the analyst's Buy rating. However, it is worth noting that Eli Lilly is trading at high valuation multiples across various metrics, which investors should consider in their decision-making process.
For those seeking a more comprehensive analysis, InvestingPro offers 18 additional tips for Eli Lilly, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.